In addition to the p110β/δ-selective inhibitors discussed above, the selective p110α/β/δ PI3K inhibitor BAY1082439 is reported to inhibit tumor growth in a bi-allelic Pten-deficient prostate cancer transgenic mouse model, and can prevent invasive progression and reduce epithelial-to-mesenchymal transition (EMT) in the Pten-deficient, KRas+/G12D mutant mouse model of metastatic prostate cancer [188]. Here, PIK3CA is linked to prostate cancer.